Synapse - Genitourinary Oncology Service

Results (114)

Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102)

Meeting Abstract

McKay, R. R.; Heller, G.; Zhao, S.; Wulff-Burchfield, E. M.; Shah, D.; Tan, A.; Galsky, M. D.; Rosenberg, J. E.; Beltran, H.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy

Meeting Abstract

Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients

Meeting Abstract

Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
Annals of Oncology (2024)

Fulltext@MSK | Save

Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)

Journal Article

Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Miller, B. C.; Hillman, D. W.; Heller, G.; Druley, T.; Armstrong, A. J.; Morris, M. J.; Milowsky, M. I.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)

Meeting Abstract

Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)

Journal Article

Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies

Meeting Abstract

Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Hillman, D. W.; Heller, G.; Druley, T. E.; Morris, M. J.; Milowsky, M. I.; Beltran, H.; Bolton, K. L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (Alliance A031201 trial)

Journal Article

Morris, M. J.; Heller, G.; Hillman, D. W.; Bobek, O.; Ryan, C.; Antonarakis, E. S.; Bryce, A. H.; Hahn, O.; Beltran, H.; Armstrong, A. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save